MGX
Metagenomi Thera (MGX)
NASDAQ
$1.34+$0.005 (+0.38%)
Price as of Jun 03, 2026 4:10 PM EDT
  • $51.2M
    Market Cap
  • -24.86%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
Income Statement
Total Operating Revenue
25.2M
-51.79%
52.3M
N/A
Cost of Revenue
N/A
N/A
N/A
N/A
Gross Profit
25.2M
-51.79%
52.3M
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
Research and Development Expense
-94.4M
-13.51%
-109.2M
N/A
Depreciation and Amortization Expense
5.3M
-1.66%
5.4M
N/A
Total Operating Expenses
121.2M
-14.15%
141.2M
N/A
Operating Profit
-96.0M
+8.00%
-88.9M
N/A
Interest Income
9.5M
-35.67%
14.7M
N/A
Interest Expense
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
9.5M
-35.67%
14.7M
N/A
Total Nonoperating Income and Expense
8.1M
+51.73%
5.3M
N/A
Income before Taxes
-87.9M
+5.21%
-83.6M
N/A
Income Taxes
-58,000
-98.95%
-5.5M
N/A
Extraordinary Items
N/A
N/A
1.0M
N/A
Net Income
-87.9M
+12.57%
-78.1M
N/A
Net Income from Continuing Operations Applicable to Common
-87.9M
+5.21%
-83.6M
N/A
Basic EPS and Net Income
-2.36
0.00%
-2.36
N/A
Diluted EPS and Net Income
-2.36
0.00%
-2.36
N/A
Basic Weighted Average Shares
37.3M
+12.79%
33.0M
N/A
Diluted Weighted Average Shares
37.3M
+12.79%
33.0M
N/A
Balance Sheet
Cash and Cash Equivalents
41.7M
+52.35%
27.4M
N/A
Short-Term Investments
119.1M
-46.10%
220.9M
N/A
Cash and Cash Equivalents and Short-Term Investments
160.8M
-35.24%
248.3M
N/A
Total Current Assets
165.5M
-35.83%
258.0M
N/A
Accumulated Depreciation
16.0M
+41.64%
11.3M
N/A
Property and Plant and Equipment and Net
12.3M
-30.73%
17.7M
N/A
Total Long-Term Assets
836,000
+191.29%
287,000
N/A
Total Assets
221.1M
-31.88%
324.6M
N/A
Income Taxes Payable
N/A
N/A
0
N/A
Total Short-Term Debt
N/A
N/A
N/A
N/A
Total Current Liabilities
22.9M
-38.53%
37.3M
N/A
Total Long-Term Debt
N/A
N/A
N/A
N/A
Total Long-Term Liabilities
2.0M
-2.84%
2.0M
N/A
Total Liabilities
62.5M
-30.35%
89.7M
N/A
Retained Earnings
-310.9M
+39.40%
-223.0M
N/A
Total Stockholders Equity
158.6M
-32.47%
234.9M
N/A
Total Shares Outstanding
37.6M
+0.54%
37.4M
N/A
Cash Flow
Cash from Operating Activities
-88.9M
-18.50%
-109.1M
N/A
Capital Expenditures
574,000
-81.57%
3.1M
N/A
Cash from Investing Activities
103.5M
+217.44%
-88.2M
N/A
Dividends Paid
N/A
N/A
N/A
N/A
Cash from Financing Activities
-356,000
-100.42%
84.0M
N/A
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
Operating Margin
-380.85%
N/A
N/A
N/A
Return on Assets
-32.20%
N/A
N/A
N/A
Return on Equity
-44.67%
N/A
N/A
N/A
Revenue Growth
-51.79%
N/A
N/A
N/A
Current Ratio
7.22
N/A
N/A
N/A
Cash Ratio
1.82
N/A
N/A
N/A
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow